Company Overview - StubHub operates a ticketing marketplace for live event tickets worldwide [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving StubHub Holdings, Inc. This includes examining whether StubHub and its top executives made materially false and/or misleading statements or omitted material information regarding the company's business and operations [1][2] Legal Firm Background - Robbins Geller Rudman & Dowd LLP is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024 alone. The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years [3]

Core Insights - Mayfair Gold Corp. reported its operating and financial results for Q3 2025, focusing on the Fenn-Gib gold project in Northeast Ontario [1][2] - The company completed a $40 million LIFE Offering to fund the advancement of the Fenn-Gib project, including permitting and engineering [2] - A Pre-Feasibility Study (PFS) for a 4,800 tpd open pit operation is underway, with completion expected in Q4 2025 [2][8] Financial Highlights - For the three months ended September 30, 2025, the company reported a loss of CAD 2,241,177 compared to CAD 1,434,837 in the same period of 2024 [7] - The loss per share for Q3 2025 was CAD 0.02, an increase from CAD 0.01 in Q3 2024 [7] - As of September 30, 2025, cash and cash equivalents totaled CAD 41,814,681, significantly up from CAD 9,534,129 a year earlier [7] Project Development - The Fenn-Gib project hosts an Indicated Resource of 181.3 million tonnes grading 0.74 g/t Au, equating to 4.3 million contained gold [8] - A confidence drilling program commenced in October 2025 to refine waste to ore boundaries and enhance grade profile confidence [2] - Formal provincial permitting activities for the project are expected to start in early 2026 [2] Corporate Governance - During the Annual General and Special Meeting on September 4, 2025, shareholders approved the re-election of board members and a new 10% rolling Omnibus Incentive Plan [6]

Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [3]. - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a record settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Molina Healthcare failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and the impact on financial guidance for fiscal year 2025 [5]. - Specific claims include a dislocation between premium rates and medical costs, reliance on limited service utilization for growth, and misleading positive statements about the company's business prospects [5].

Core Points - Rosen Law Firm is reminding purchasers or sellers of Cepton, Inc. common stock during the Class Period from July 29, 2024, to January 6, 2025, about the December 8, 2025, lead plaintiff deadline [1] - Investors who participated in the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Legal Action Details - A class action lawsuit has been filed against Cepton, Inc. for making materially false and misleading statements regarding its business and operations during the Class Period [5] - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5] Next Steps for Investors - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7]

Core Insights - Vanda Pharmaceuticals has announced positive topline results from a clinical study of tradipitant, indicating its potential as a key adjunct in the over $50 billion global GLP-1 agonist market [1][4]. Study Results - The study showed that only 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% in the placebo group, achieving a 50% relative reduction (p=0.0016) [2][4]. - The secondary endpoint was also met, with 22.4% of the tradipitant group experiencing vomiting and significant nausea, versus 48.3% in the placebo group (p=0.0039) [2][4]. Safety Profile - Tradipitant exhibited a favorable safety profile, consistent with previous studies, with no new safety signals reported [3][4]. Market Implications - The efficacy of tradipitant in reducing nausea and vomiting could significantly improve adherence to GLP-1 agonist treatments, which currently face a 30-50% discontinuation rate due to gastrointestinal side effects [5][6]. - The global GLP-1 agonist market is projected to exceed $50 billion, highlighting the potential financial impact of tradipitant's success [4][5]. Future Development - Vanda plans to initiate a Phase III program for tradipitant in the first half of 2026, aiming for regulatory approval to address the unmet need in managing GLP-1 induced nausea and vomiting [7][9].

Accessibility StatementSkip Navigation NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a co ...

Accessibility StatementSkip Navigation A partnership including: REDF, SRC LCM Partners LONDON, Nov. 17, 2025 /PRNewswire/ -- Under the patronage and presence of His Excellency Mr. Majed bin Abdullah Al-Hogail, Minister of Municipal and Rural Affairs and Housing and Chairman of the Board of the Real Estate Development Fund, the Real Estate Development Fund (REDF) and the Saudi Real Estate Refinance Company (SRC), announced the signing of a tripartite partnership with LCM Partners. LCM Partners is one of Euro ...

Core Viewpoint - Ceva, Inc. has initiated a public offering of 3,000,000 shares of its common stock, with an option for underwriters to purchase an additional 450,000 shares, aimed at enhancing financial flexibility and funding potential acquisitions [1][2]. Group 1: Offering Details - The public offering consists of 3,000,000 shares, with a 30-day option for underwriters to buy an additional 450,000 shares [1]. - The shares are expected to be listed on the Nasdaq Global Select Market [1]. - J.P. Morgan is the lead book-running manager, with UBS Investment Bank as the junior active book-running manager, and several other firms acting as additional book-running managers and co-managers [3]. Group 2: Purpose of the Offering - The primary purposes of the offering are to increase financial flexibility, obtain additional capital, and enhance the public float [2]. - Net proceeds from the offering will be used for potential acquisitions, investments in complementary technologies, working capital, capital expenditures, share repurchases, and other general corporate purposes [2]. Group 3: Company Overview - Ceva, Inc. specializes in wireless communications, sensing, and Edge AI technologies, powering over 20 billion smart edge products globally [5]. - The company offers a broad portfolio of IP solutions for various applications, including AI-infused devices, IoT, and 5G mobile networks [5].

Core Insights - CytoSorbents Corporation will present and engage in one-on-one meetings with investors at the Jefferies Global Healthcare Conference from November 17-20, 2025 in London [1][9] - The presentation is scheduled for November 18, 2025, at 12:30 PM GMT / 7:30 AM ET, with a live webcast available [2] Company Overview - CytoSorbents Corporation specializes in treating life-threatening conditions in intensive care and cardiac surgery through blood purification technologies [3] - The company's proprietary technology utilizes biocompatible, highly porous polymer beads to remove toxic substances from blood and bodily fluids [3] - Key applications include the removal of blood thinners during cardiothoracic surgery and the elimination of inflammatory agents in critical illnesses such as sepsis and liver failure [3] Product Information - The lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries, with nearly 300,000 devices used to date [4] - CytoSorb has received FDA Emergency Use Authorization for critically ill COVID-19 patients in the U.S., although it is not yet fully approved in the U.S. [4] - The company is developing the DrugSorb™-ATR system to reduce perioperative bleeding in high-risk surgeries, which has received two FDA Breakthrough Device Designations [5] Research and Development - CytoSorbents has a range of marketed products and ongoing developments protected by numerous patents and trademarks [6] - The company is actively pursuing regulatory approvals for its products in the U.S. and Canada [5]